General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises the Underwriters in Spruce Biosciences’ Initial Public Offering

October 9, 2020
A life sciences capital markets team advised the underwriter in pricing of the biopharmaceutical company’s initial public offering.
Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on October 9, 2020 under the symbol “SPRB”. 
Latham & Watkins LLP represents the underwriters in the offering with a life sciences-focused capital markets team led by Bay Area partner Brian Cuneo and Orange County partner Drew Capurro, with Orange County associates Nicole Jazayeri and Mekbeb Hagos. Advice was also provide on benefits and compensation matters by San Diego partner Holly Bauer, with Los Angeles associate Rachel Narowski; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang and Heather Deixler, with Washington, D.C. associates Barrett Tenbarge and Lacey Henry; on intellectual property matters by Bay Area partner Judith Hasko, with New York associate Jiqiang Lin; and on tax matters by Bay Area partner Grace Lee, with Orange County associate Janet Hsu.